Aberrant methylation of CCAAT/enhancer binding protein zeta promoter in acute myeloid leukemia

作者：Yao, Dong-Ming; Qian, Jun; Lin, Jiang^*; Wang, Ya-Li; Chen, Qin; Qian, Zhen; Li, Yun; Wang, Cui-Zhu; Yang, Jing

来源：Leukemia Research, 2011, 35(7): 957-960.

DOI：10.1016/j.leukres.2010.10.031

• AML
• C/EBP zeta
• Methylation

The aberrant changes of tumor suppressor genes (TSGs) are now recognized as an important mechanism contributing to the development of acute myeloid leukemia (AML). CCAAT/enhancer binding protein zeta (C/EBP zeta), a candidate TSG, has been found to be involved in cancers including AML. We detected the methylation status of C/EBP zeta promoter in 133 patients with AML using the methylation-specific polymerase chain reaction (MS-PCR) and examined C/EBP zeta transcript in 32 patients using real-time quantitative PCR. The abnormal methylation of C/EBP zeta gene promoter was found in 62 (46.6%) AML cases. No correlation was found between C/EBP zeta promoter hypermethylation and the age, sex, WBC counts, platelet counts and FAB subtypes of AML patients (P > 0.05). The trend that the frequency of C/EBP zeta methylation increased as karyotype became more adverse was observed (R = 0.167, P = 0.075). There was a significant correlation between C/EBP zeta expression and C/EBP zeta methylation in AML patients (R = 0.606, P = 0.002). Our data suggest that the aberrant methylation of C/EBP promoter may be involved in AML.

• 出版日期2011-7
• 单位江苏大学